Vitiligo
Not recruitingStudy on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Germany- Participants:18–64 years · 65+ years
- Substances:MK-6194
- Sponsor:Merck Sharp & Dohme LLC
Rare diseases
Investigational molecules
Locations
Back to Germany1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
GermanyStudy on the Effects of EP262 for Adults with Chronic Spontaneous Urticaria
GermanyStudy of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment
GermanyStudy on Nicotine Freshmint Mouthspray for E-cigarette Users Looking to Quit
GermanyStudy Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer
GermanyStudy of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment
GermanyStudy on Filgotinib for Children and Teens with Juvenile Idiopathic Arthritis
GermanyStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
GermanyStudy on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion
GermanyStudy Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy
GermanyStudy on the Effectiveness and Safety of Oral Minoxidil for Women with Androgenetic Alopecia
GermanyStudy on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation
GermanyThe busiest research cities in the country
What the registry says about research in the country
Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.
The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.
Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.
Research aims to enhance progression-free survival through targeted therapeutic strategies.
Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.
Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.
Tell us about your condition – we search every trial in Europe and connect you with the right site.